Sanofi, Re­gen­eron boast PhI­II win with Dupix­ent in COPD, clear­ing first bar for ex­pan­sion

Dupix­ent, the block­buster an­ti-in­flam­ma­to­ry drug from Sanofi and Re­gen­eron, has cleared a high-stakes Phase III study in chron­ic ob­struc­tive pul­monary dis­ease, the com­pa­nies an­nounced Thurs­day morn­ing.

If they hold up in a sec­ond, iden­ti­cal tri­al, the da­ta pave the way for Dupix­ent to be­come the first bi­o­log­ic to treat pa­tients whose COPD re­mains un­con­trolled de­spite be­ing on max­i­mal stan­dard-of-care in­haled ther­a­py — the pa­tient pop­u­la­tion stud­ied in the piv­otal pro­gram. The com­pa­nies had spot­light­ed this as a key read­out as they look to ex­pand the Dupix­ent fran­chise and ex­plore its full po­ten­tial.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN